Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Skin Infection
Bacterial Infection

Interventions

DRUG: Daptomycin
DRUG: Brilacidin

Sponsor

Cellceutix Corporation